According to Galmed Pharmaceuticals 's latest financial reports the company's current earnings (TTM) are -$6.36 M. In 2022 the company made an earning of -$17.87 M an increase over its 2021 earnings that were of -$32.47 M.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$6.92 M | -61.31% |
2022 | -$17.87 M | -44.97% |
2021 | -$32.47 M | 12.85% |
2020 | -$28.78 M | 40.61% |
2019 | -$20.47 M | 109.19% |
2018 | -$9.79 M | -20.47% |
2017 | -$12.3 M | -27% |
2016 | -$16.85 M | 58.6% |
2015 | -$10.63 M | 16.7% |
2014 | -$9.11 M | -47.94% |
2013 | -$17.49 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Evoke Pharma
EVOK | -$6.63 M | 4.26% | ๐บ๐ธ USA |
Endo International
ENDPQ | -$2.4 B | 37,526.55% | ๐ฎ๐ช Ireland |
Aerie Pharmaceuticals AERI | -$23.25 M | 265.60% | ๐บ๐ธ USA |
Catalent CTLT | -$1 B | 15,583.50% | ๐บ๐ธ USA |